Alpha IVF Group Berhad Full Year 2025 Earnings: Misses Expectations
Key Financial Results
Revenue: RM176.8m (up 5.5% from FY 2024).
Net income: RM57.5m (up 8.5% from FY 2024).
Profit margin: 33% (in line with FY 2024).
EPS: RM0.012 (in line with FY 2024).
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alpha IVF Group Berhad Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 13%.
The primary driver behind last 12 months revenue was the Malaysia segment contributing a total revenue of RM157.2m (89% of total revenue). The largest operating expense was General & Administrative costs, amounting to RM33.1m (67% of total expenses). Explore how ALPHA's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Healthcare industry in Malaysia.
Performance of the Malaysian Healthcare industry.
The company's shares are up 5.5% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 2 warning signs for Alpha IVF Group Berhad (1 makes us a bit uncomfortable!) that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
DuPont Lifts Outlook On Strong Demand In Key Markets
DuPont de Nemours, Inc. (NYSE:DD) stock gained on Tuesday after it beat second-quarter expectations on both earnings and revenue and raised its full-year adjusted earnings outlook, citing strong demand across electronics, healthcare, and water markets. The company reported adjusted earnings per share of $1.12 for the quarter, above the $1.06 analyst estimate. Net sales rose 3% year-over-year to $3.26 billion, topping the $3.23 billion consensus. Sales growth was driven by a 4% increase in volume, partially offset by a 2% decline in price. Organic sales rose 2%. Also Read: GAAP income from continuing operations was $238 million, or 54 cents per share, compared with $176 million, or 40 cents per share, in the same period last year. Adjusted EPS rose 15% from the prior-year quarter, driven by higher segment earnings and a lower tax rate. Operating EBITDA increased 8% to $859 million, with margin expanding 120 basis points to 26.4%. Cash provided by operating activities from continuing operations totaled $381 million. After $116 million in capital expenditures and $168 million in separation-related transaction costs, transaction-adjusted free cash flow reached $433 million. View more earnings on DD ElectronicsCo reported a 6% increase in sales to $1.17 billion, supported by 8% volume growth. Semiconductor Technologies grew in the mid-single digits, while Interconnect Solutions rose in the high-single digits. Segment operating EBITDA rose 14% to $373 million, with margin improving 220 basis points to 31.9%. IndustrialsCo sales increased 1% to $2.09 billion, with 2% volume growth offset by a 1% price decline. Healthcare & Water Technologies grew in the high single digits, while Diversified Industrials declined due to ongoing weakness in construction markets. Segment operating EBITDA rose 3% to $509 million, with margin improving 50 basis points to 24.4%. DuPont ended the quarter with $1.84 billion in cash and $5.33 billion in long-term debt. The company confirmed it remains on schedule for the planned Nov. 1, 2025, spin-off of its Electronics business, Qnity. CEO Lori Koch stated, "Ongoing strength in electronics, healthcare and water end-markets, along with our team's focus on operational execution continued to drive strong earnings growth and cash conversion." Outlook The company raised its full-year 2025 adjusted EPS guidance from a prior range of $4.30–$4.40 to approximately $4.40, exceeding the $4.26 analyst estimate. It also narrowed its full-year net sales forecast from $12.80–$12.90 billion to $12.85 billion, ahead of the $12.78 billion consensus. Guidance now includes a $20 million headwind from tariffs, or 4 cents per share. For the third quarter, DuPont expects adjusted EPS of $1.15 and revenue of $3.32 billion, ahead of analyst estimates of $1.13 and $3.29 billion, respectively. Price Action: At last check Tuesday, DD shares were trading higher by 5.9% to $74.52 premarket. Read Next:Photo by Sundry Photography via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? DUPONT DE NEMOURS (DD): Free Stock Analysis Report This article DuPont Lifts Outlook On Strong Demand In Key Markets originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Rivian Q2 earnings preview: EV tax credit impact, R2 SUV update on the agenda
Rivian (RIVN) will report second quarter earnings after the bell on Tuesday, as the pure-play EV-maker builds the case towards eventual profitability, while navigating the minefields of President Trump's auto sector tariffs and removal of EV tax credits. For the quarter, Rivian is expected to report revenue of $1.28 billion per Bloomberg consensus estimates, and higher than the $1.158 billion reported a year ago. The company is expected to post an adjusted EPS loss of $0.63, with an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss of $493 million. Last quarter the company reported its second consecutive quarter of gross profit, hitting $206 million. Despite this, issues like trade policy and tariffs meant the maintained its 2025 full-year adjusted EBITDA loss projection in a range of $1.7 billion to $1.9 billion. Tariffs on auto parts currently stand at 25%, though USMCA compliant parts are exempt. Federal EV tax credits expiring at the end of September will likely hurt Rivian's ability to scale up sales and generate more gross profit. The company said in early July it produced 5,979 vehicles at its Normal, Illinois, factory and delivered 10,661 vehicles during the second quarter, which was slightly below 10,800 analysts' consensus. Production was limited during the quarter in preparation for model year 2026 vehicles expected to launch later this month, the company said. Rivian reaffirmed its 2025 delivery guidance range of 40,000 to 46,000 vehicles, though this is below the company's original 2025 target of deliveries between 46,000 and 51,000. The loss of the federal $7,500 federal tax credit may impact its delivery and EBITDA loss forecast, though it may pull forward sales in Q3 leading to a strong sales quarter. The development of Rivian's upcoming R2 midsize crossover will be a big focus in Rivian's report and the following analyst conference call. 'On the call, we'll be looking for further detail on Rivian's progress with its Volkswagen Joint Venture (total deal size of ~$5.8B), and on the company's progress towards autonomy, and towards commercializing its R2 line, which is slated for SOP [start of production] in 1H26,' wrote Cantor Fitzgerald analyst Andres Sheppard. Deutsche Bank's Edison Yu adds that R2 prototypes have been seen in the wild, further suggesting 2026 production is in the cards, but there are still headwinds for the business overall. 'Heading into 2H, we worry that EV policy headwinds could keep a lid on the stock. Moreover, the company is expected to experience some downtime related to R2, hurting overhead absorption,' he wrote in late July. Pras Subramanian is the lead auto reporter for Yahoo Finance. You can follow him on X and on Instagram.
Yahoo
26 minutes ago
- Yahoo
Viatris Stock: Analyst Estimates & Ratings
Viatris Inc. (VTRS), headquartered in Canonsburg, Pennsylvania, operates as a healthcare company. With a market cap of $10.3 billion, the company produces medicines for patients across a broad range of major therapeutic areas spanning both noncommunicable and infectious diseases. Shares of this global healthcare giant have considerably underperformed the broader market over the past year. VTRS has declined 24.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 18.4%. In 2025, VTRS stock is down 28.2%, compared to the SPX's 7.6% rise on a YTD basis. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Narrowing the focus, VTRS' underperformance looks less pronounced compared to the iShares U.S. Pharmaceuticals ETF (IHE). The exchange-traded fund has declined 1% over the past year. Moreover, the ETF's 3.4% gains on a YTD basis outshine the stock's double-digit losses over the same time frame. Viatris' performance has been impacted by a setback in its generics segment due to an FDA import alert on its Indore facility, which has restricted product shipments. The company is actively working with the FDA to resolve the issue. Viatris shares rose 5.7% on May 8 after the company reported Q1 earnings that beat expectations. Despite an 11.2% year-over-year decline in revenue to $3.3 billion, the figure topped consensus estimates. The company's adjusted EPS of $0.50, although down 25.4% from the previous year, also beat analyst expectations by 2%. For the current fiscal year, ending in December, analysts expect VTRS' EPS to decline 15.1% to $2.25 on a diluted basis. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. Among the seven analysts covering VTRS stock, the consensus is a 'Hold.' That's based on one 'Strong Buy' rating, five 'Holds,' and one 'Moderate Sell.' The configuration has been reasonably stable over the past three months. On Jul. 15, The Goldman Sachs Group, Inc. (GS) analyst reiterated a 'Hold' rating on VTRS and set a price target of $10, implying a potential upside of 11.9% from current levels. The mean price target of $11.18 represents a 25.1% premium to VTRS' current price levels. The Street-high price target of $14 suggests a notable upside potential of 56.6%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
